Supplementary Figure S8 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
Abstract
Figure S8. Nanobody-based CAR T cells represent an effective and compact alternative to scFv-based CAR constructs
Fields of Study & Subjects
CAR-T cell therapy research
T-cell and B-cell Immunology
Monoclonal and Polyclonal Antibodies Research
Publication details
- Publication date
- 11 March 2026
- Language
- EN